Anitocabtagene autoleucel clinical trials
Also written CART-ddBCMA.
How each study uses anitocabtagene autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the anitocabtagene autoleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2019 (1); 2 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test anitocabtagene autoleucel.
- Dec 2026Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Phase 2 · Kite, A Gilead Company
Studies
Open first, then newest update. How each study uses anitocabtagene autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07903506Written as Anitocabtagene Autoleucel
- Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruitingPhase 1Kite, A Gilead CompanyNCT06626919Written as anito-cel
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07887672Written as Anitocabtagene autoleucel
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT06413498Written as Anitocabtagene Autoleucel
- Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaActive, not recruitingPhase 1Kite, A Gilead CompanyNCT04155749Written as anitocabtagene-autoleucel
- Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Active, not recruitingPhase 2Kite, A Gilead CompanyNCT05396885Written as anitocabtagene-autoleucel
Given beside what is tested · 1 — anitocabtagene autoleucel is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaOct 29, 2026NCT07903506
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaOct 21, 2026NCT07887672
Codes
What other systems call anitocabtagene autoleucel · ClinicalTrials.gg INT018376
- UNII (FDA) WQD5K35YZTANITOCABTAGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C199003Anitocabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WQD5K35YZT | ANITOCABTAGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C199003 | Anitocabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.